TITLE:
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

CONDITION:
Alzheimer's Disease

INTERVENTION:
AVP-923

SUMMARY:

      The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of
      Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes
      of uncontrolled crying and/or laughter).
    

DETAILED DESCRIPTION:

      This is an "open label" study which means there is no placebo group. Each subject enrolled
      into the study will receive AVP-923.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  18 to 75 years of age, inclusive

          -  Clinical diagnosis of PBA (pseudobulbar affect)

          -  If female, must not be pregnant or breast feeding

        Exclusion Criteria:

          -  Sensitivity to quinidine or any opiate drugs

          -  Current or prior history of major psychiatric disturbance

          -  Currently participated in a trial within the past 30 days
      
